Safety assessments
Cancer, blood coagulation
ADVERSE EVENT, ADVERSE EVENT, CANCER
Adverse events (AEs) were monitored from the time of informed consent until 30 days after the last study drug administration. Safety assessments included evaluation of vital signs, physical examination, ophthalmic examination, ECOG performance status, clinical laboratory tests (routine blood tests, blood biochemistry, blood coagulation function and standard urinalysis), 12-lead electrocardiogram, and echocardiogram. The severity of AEs was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).